Djokic-Gallagher Jasmina, Rosher Phil, Hart Valerie, Walker Jennine
Research and Development, Dermal Laboratories Ltd, Hitchin, SG4 7QR, UK.
Clin Cosmet Investig Dermatol. 2019 Aug 2;12:545-552. doi: 10.2147/CCID.S210444. eCollection 2019.
Adex gel (DENI) is a leave-on emollient, containing an ancillary anti-inflammatory medicinal substance, nicotinamide, for use in the treatment and management of dry skin conditions prone to inflammation. The aim of the study was to obtain patients' and a Medical Investigator's feedback on the clinical performance and acceptability of the product, and to assess the product's potential for reducing patients' reliance on topical corticosteroids and immunomodulators. Forty-eight patients were enrolled with 43 patients completing the study. These patients used the product on its own, or as adjunctive therapy, for two weeks instead of their usual emollient, applying it three times daily or more often if necessary. Using a questionnaire, subjects then indicated whether they were in agreement or not with various statements about the clinical performance and acceptability of the product. In the second part of the study, twenty patients used the product for four weeks, this time using it as often as they liked. The Medical Investigator looked at both the performance and the acceptability of the treatment. Patients completed a questionnaire again to indicate how they used it and whether their use of topical corticosteroids and/or immunomodulator treatments had changed. Patient's responses were very positive, ranging from 81% to 100% agreement with each performance statement in relation to beneficial effects on the skin. The Medical Investigator considered that for nearly all patients, DENI gel was a helpful and convenient addition to their treatment regime. When questioned on steroid-sparing effects, more than half reported that they needed to use less of their other anti-inflammatory treatments, and nearly 95% reported that they felt their skin condition had benefited from using DENI gel. This new anti-inflammatory emollient appears to be a helpful addition to the treatment armamentarium for eczema and psoriasis that may reduce reliance on topical corticosteroids and immunomodulators.
阿德克斯凝胶（DENI）是一种免洗润肤剂，含有辅助抗炎药物烟酰胺，用于治疗和管理易发炎的干性皮肤状况。该研究的目的是获得患者和医学研究者对该产品临床性能和可接受性的反馈，并评估该产品减少患者对局部用皮质类固醇和免疫调节剂依赖的潜力。48名患者入组，43名患者完成了研究。这些患者单独使用该产品，或作为辅助治疗，持续两周，取代他们常用的润肤剂，必要时每天涂抹三次或更频繁。然后，受试者通过问卷表明他们是否同意关于该产品临床性能和可接受性的各种陈述。在研究的第二部分，20名患者使用该产品四周，这次他们根据自己的喜好使用。医学研究者观察了治疗的性能和可接受性。患者再次填写问卷，以表明他们如何使用该产品，以及他们对局部用皮质类固醇和/或免疫调节剂治疗的使用是否发生了变化。患者的反应非常积极，对于与皮肤有益效果相关的每项性能陈述，同意率从81%到100%不等。医学研究者认为，对于几乎所有患者来说，DENI凝胶是他们治疗方案中一种有用且方便的补充。当被问及对类固醇的节省作用时，超过一半的患者报告说他们需要减少其他抗炎治疗的用量，近95%的患者报告说他们觉得使用DENI凝胶使他们的皮肤状况受益。这种新型抗炎润肤剂似乎是湿疹和牛皮癣治疗手段的一种有益补充，可能会减少对局部用皮质类固醇和免疫调节剂的依赖。
